Selective Estrogen Receptor Modulators (SERMs) for the treatment of ER+ breast cancer: An overview

Simple item page
dc.contributor.authorDas, Sweety
dc.contributor.authorKulkarni, Swanand
dc.contributor.authorSingh, Yogesh
dc.contributor.authorKumar, Pradeep
dc.contributor.authorThareja, Suresh
dc.date.accessioned2024-01-21T10:38:23Z
dc.date.accessioned2024-08-13T12:05:19Z
dc.date.available2024-01-21T10:38:23Z
dc.date.available2024-08-13T12:05:19Z
dc.date.issued2022-08-02T00:00:00
dc.description.abstractBreast cancer is a major threat to women's lives throughout the world. Hormone-dependent or estrogen-receptor positive (ER+) breast cancer accounts for more than 80% of all instances. Selective Estrogen Receptor Modulators (SERMs), which specifically control the ERs and limit the progression of breast malignancy, have drawn the interest of researchers in the treatment of breast cancer by regulation of the estrogen receptors (ER), particularly ER?. The mode of action, anti-proliferative potential, SAR, and favourable interactions of the potent candidates are elaborated. Many potent SERMs with diversity in structural space have been rationally designed and reported in the literature for their anti-breast cancer activity. These SERMs exhibited remarkable anti-proliferative activity against ER+ BC. Since, ER? is responsible for the initiation and progression of BC, there is an urgent need to strategically design and synthesize new SERMs, having more selective binding towards ER?. Long term use of traditionally marketed SERMs is associated with several adverse effects, such as development of endometrial cancer and other disorders. Insight of structural features in the present review will prove to be a guideline for the researchers to design and develop potent SERMs for the treatment of ER+ breast cancer. � 2022 Elsevier B.V.en_US
dc.identifier.doi10.1016/j.molstruc.2022.133853
dc.identifier.issn222860
dc.identifier.urihttp://10.2.3.109/handle/32116/3555
dc.identifier.urlhttps://linkinghub.elsevier.com/retrieve/pii/S0022286022015071
dc.language.isoen_USen_US
dc.publisherElsevier B.V.en_US
dc.subjectBreast canceren_US
dc.subjectEstrogen receptor ?en_US
dc.subjectMalignancyen_US
dc.subjectSelective estrogen receptor modulatorsen_US
dc.titleSelective Estrogen Receptor Modulators (SERMs) for the treatment of ER+ breast cancer: An overviewen_US
dc.title.journalJournal of Molecular Structureen_US
dc.typeReviewen_US
dc.type.accesstypeClosed Accessen_US

Files

Collections

Pharmaceutical Sciences and Natural Products - Research Publications